Literature DB >> 16024862

Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial.

A R Ramezani1, H Ahmadieh, A K Ghaseminejad, S Yazdani, B Golestan.   

Abstract

AIMS: To evaluate the effect of tranexamic acid on early postvitrectomy haemorrhage in diabetic patients.
METHODS: In a clinical trial, 62 diabetic patients scheduled for vitrectomy were randomly assigned to two groups. The treatment group (32 eyes) received two doses of tranexamic acid (10 mg/kg) shortly before and after the operation intravenously, continued orally for 4 days (20 mg/kg/8 hours). The control group (30 eyes) received no medication. Both media clarity and visual acuity were compared during 4 weeks.
RESULTS: Four weeks after surgery visual acuity was low (< or =1 metre counting fingers) in 21.4%, moderate (>1 metre counting fingers but<20/200) in 14.3%, and good (> or =20/200) in 64.3% of the treated group. Corresponding figures in the control group were 26.1%, 26.1%, and 47.8%, respectively. These differences were of no statistical significance. The ratio of mild to severe vitreous haemorrhage during the first 4 days and after 4 weeks was 79% to 21% and 82% to 18% in the treatment group and 76.7% to 23.3% and 78.3% to 21.7% in the control group respectively, which showed no statistically significant difference.
CONCLUSION: Tranexamic acid, with the method of administration in this study, had no effect on reducing early postvitrectomy haemorrhage in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024862      PMCID: PMC1772792          DOI: 10.1136/bjo.2004.062638

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Sodium hyaluronate (Healon) in closed vitrectomy.

Authors:  J C Folk; A J Packer; T A Weingeist; M J Howcroft
Journal:  Ophthalmic Surg       Date:  1986-05

2.  Tranexamic acid reduces blood loss in total hip replacement surgery.

Authors:  G Ekbäck; K Axelsson; L Ryttberg; B Edlund; J Kjellberg; J Weckström; O Carlsson; U Schött
Journal:  Anesth Analg       Date:  2000-11       Impact factor: 5.108

3.  Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.

Authors:  S T Hiippala; L J Strid; M I Wennerstrand; J V Arvela; H M Niemelä; S K Mäntylä; R P Kuisma; J E Ylinen
Journal:  Anesth Analg       Date:  1997-04       Impact factor: 5.108

4.  Effect of tranexamic acid on postvitrectomy haemorrhage in diabetic patients.

Authors:  L Laatikainen; P Summanen; I Immonen
Journal:  Int Ophthalmol       Date:  1987-06       Impact factor: 2.031

5.  Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1.

Authors: 
Journal:  Ophthalmology       Date:  1985-04       Impact factor: 12.079

6.  Intraocular hemocoagulase in human vitrectomy.

Authors:  S H Kim; Y S Cho; Y J Choi
Journal:  Jpn J Ophthalmol       Date:  1994       Impact factor: 2.447

7.  Hemostatic effects of air versus fluid in diabetic vitrectomy.

Authors:  B C Joondeph; G W Blankenship
Journal:  Ophthalmology       Date:  1989-12       Impact factor: 12.079

8.  The use of intravitreal thrombin to control hemorrhage during vitrectomy.

Authors:  J T Thompson; B M Glaser; R G Michels; S de Bustros
Journal:  Ophthalmology       Date:  1986-03       Impact factor: 12.079

9.  Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage.

Authors:  S de Bustros; B M Glaser; R G Michels; C Auer
Journal:  Arch Ophthalmol       Date:  1985-02

10.  Procoagulant effects of intraocular sodium hyaluronate (Healon) after phakic diabetic vitrectomy. A prospective, randomized study.

Authors:  A J Packer; B W McCuen; W L Hutton; R C Ramsay
Journal:  Ophthalmology       Date:  1989-10       Impact factor: 12.079

View more
  9 in total

1.  Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression.

Authors:  Isabel Taeuber; Stephanie Weibel; Eva Herrmann; Vanessa Neef; Tobias Schlesinger; Peter Kranke; Leila Messroghli; Kai Zacharowski; Suma Choorapoikayil; Patrick Meybohm
Journal:  JAMA Surg       Date:  2021-04-14       Impact factor: 14.766

Review 2.  Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

3.  The use of antivascular endothelial growth factor agents in the perioperative period in diabetic vitrectomy.

Authors:  Nakhleh E Abu-Yaghi; Sophie J Bakri
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

4.  Sulfur Hexafluoride 20% versus Lactated Ringer's Solution for Prevention of Early Postoperative Vitreous Hemorrhage after Diabetic Vitrectomy.

Authors:  Fereydoun Farrahi; Mostafa Feghhi; Biuk Bagherzadeh; Mahmood Latifi
Journal:  J Ophthalmic Vis Res       Date:  2010-04

5.  The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy.

Authors:  Abdullah Al-Kharashi; Tural Galbinur; Efrem D Mandelcorn; Rajeev H Muni; Mir Nabavi; Peter J Kertes
Journal:  Saudi J Ophthalmol       Date:  2016-10-29

6.  The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study.

Authors:  Tingting Jiang; Junxiang Gu; Peijun Zhang; Wenwen Chen; Qing Chang
Journal:  BMC Ophthalmol       Date:  2020-02-03       Impact factor: 2.209

Review 7.  Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Authors:  Jonathan M Smith; David H W Steel
Journal:  Cochrane Database Syst Rev       Date:  2015-08-07

8.  A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.

Authors:  Xiaochun Yang; Jianbiao Xu; Ruili Wang; Yan Mei; Huo Lei; Jun Liu; Ting Zhang; Haiyan Zhao
Journal:  J Ophthalmol       Date:  2016-03-13       Impact factor: 1.909

9.  Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.

Authors:  Xin-Yu Zhao; Song Xia; You-Xin Chen
Journal:  Br J Ophthalmol       Date:  2017-12-15       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.